Reason for request
Inclusion of the list of medicines reimbursed by National Insurance and approved for use by hospitals. .
Clinical Benefit
| Substantial |
The actual benefit of these drugs is substantial. |
Clinical Added Value
| minor |
INOVELON offers a minor (level IV) improvement in actual benefit in the therapeutic management of patients aged 4 and over with Lennox-Gastaut syndrome that is resistant to first-line treatments. |
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
0uc13ed2KygXxX7z
